SECOND ANNUAL PATIENT-REPORTED OUTCOME (PRO) CONSORTIUM WORKSHOP

March 15, 2011 Silver Spring, MD

Co-sponsored by

CRITICAL PATH INSTITUTE

FDA

collaborate . innovate . accelerate
FDA/NIH Interagency Outcomes Assessment Working Group: Goals & Updates

Wendy R. Sanhai, PhD, MBA
Senior Scientific Advisor
Office of the Chief Scientist, FDA

SECOND ANNUAL PATIENT-REPORTED OUTCOME (PRO) CONSORTIUM WORKSHOP

March 15, 2011 Silver Spring, MD
Co-sponsored by

CRITICAL PATH INSTITUTE
FDA
FDA-NIH Collaboration

- February 24, 2010, FDA & NIH announced the formation of a joint leadership council for Advancing Regulatory Science through Novel Research and Science-Based Technologies

- October 25, 2010 – FDA & NIH representatives meet for first meeting of the Interagency Outcomes Assessment Working Group (IOAWG)
Catalyst For IOAWG

- Improve interagency communication on outcomes assessment development and qualification

- Identify and develop opportunities for agency staff and other scientists developing outcomes assessments to:
  - Increase training and education/outreach
  - Inform the use of scarce resources and staff-time toward direct patient benefit
  - Identify opportunities for joint activities re: data acquisition, annotation and management to develop standards, best practices and inform clinical and regulatory decision-making
  - Increase transparency of respective activities

- Provide transparency and regulatory assistance related to the qualification process...as outlined in the draft DDT guidance
Clinical Outcomes Assessments

Definition Includes:

- Patient-Reported Outcomes
- Clinician-Reported Outcomes
- Observer-Reported Outcomes

**NOT** “Biomarkers”
Objectives of IOAWG

- To increase communication between FDA and the many separate efforts at NIH to advance measurement science and knowledge base for improving clinical outcomes
- To help the parties understand and inform the regulatory processes for evaluation of the clinical outcomes assessments
- To foster appropriate evidence generation toward the qualification of novel clinical outcomes assessments
- To leverage public and private efforts toward consensus and standards development in this area
IOAWG Membership

- **FDA:**
  - Office of the Commissioner
  - Center for Drug Evaluation and Research
  - Center for Devices and Radiological Health
  - Center for Biologics Evaluation and Research
- **NIH**
  - Office of the Director
  - 6 ICs: NCI, NIA, NIAMS, NICHD, NINDS, NHLBI (perhaps more...)
- Additional representation as needed
Updates...

• Established regular meetings (3 meetings to date)

• Drafted work group charter and memo to inform FDA/NIH Leadership Council

• Drafted overall objectives
  • Described qualification process for outcomes
  • Developing categories of clinical outcomes assessment used in research: Definitions, dimensions end evidence needed for intended use

• Identified a list of preliminary projects/workstreams
  • Project Inventory (being developed)
  • Education & Outreach priorities (will be developed)
Project Inventory: Goals

• Developing comprehensive inventory of activities related to development of OA instruments at NIH & FDA:
  • Identify scientific/unmet public health need
  • Evaluate on-going activities for its readiness to enter into the qualification process
  • Identify efforts that may not realize overarching agency-goals and modify accordingly
Education and Outreach

• Identify opportunities for educating scientific community on development, clinical qualification, and use of OA tools:
  • Workshops
  • Web pages
  • Scientific publications
  • Foster collaboration with multiple stakeholders and sharing outcomes early and openly
Summary

• FDA & NIH have identified the benefits of working together to advance the development and qualification of outcomes assessment tools toward patient benefit and to inform product development

• NIH-developed products will be entered into DDT qualification process, when they are ready

• FDA & NIH will assure that all outcomes of this collaboration are accessible by all